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Remifentanil Reduces the Release of Biochemical Markers of Myocardial
Damage After Coronary Artery Bypass Surgery. A Randomized Trial
Gordon T.C. Wong, MB, BS, FANZCA,* Zhiyong Huang, MD,† Shangyi Ji,‡ and Michael G. Irwin, MD, FRCA*
Objective: Opioids, including remifentanil, have been
demonstrated to confer cardiac protection against ischemia
reperfusion injury in animals. This study evaluates whether
remifentanil preconditioning is protective in first time elec-
tive on pump coronary artery bypass surgery patients re-
ceiving a standardized fentanyl (25 g/kg in total) and
propofol anesthetic.
Design: A prospective, double blind, randomized, con-
trolled study.
Setting: University hospital; single institutional.
Participants: Forty patients scheduled for first time elec-
tive, on pump coronary artery bypass surgery for at least 3
diseased vessels.
Interventions: Patients randomized to the remifentanil
group (n  20) received a 1 g/kg bolus followed by 0.5
g/kg/min infusion for 30 minutes after induction but be-
fore sternotomy, whilst the control group (n  20) received
normal saline. Serial samples for measurement of creatine
kinase (CKMB), cardiac troponin I (cTnI), ischemia modified
albumin (IMA) and heart type fatty acid binding protein
(hFABP) were taken at baseline, pre bypass, T  10 minutes,
2, 6, 12, and 24 hours after cross clamp release, to assess the
degree of myocardial damage.
Measurements and Main Results: Patients in the remifen-
tanil group had lower levels of CKMB from T  2 hours to 24
hours, cTnI from T  10 minutes to T  12 hours, IMA from
T  10 min to T  2 hours and h-FABP from T  10 minutes
to T  12 hours (p < 0.05). The time to tracheal extubation
was shorter in patients in the remifentanil group. The overall
length of ICU and hospital stays was not different.
Conclusions: The addition of remifentanil to the anesthe-
sia regimen reduced the degree of myocardial damage. This
incremental benefit may be attributable to either to remifen-
tanil itself or to an overall increased opioid dose, the latter
may be necessary to trigger cardiac protection.
© 2009 Elsevier Inc. All rights reserved.
KEY WORDS: myocardial protection, opioid, remifentanil,
cardiac surgery
ANUMBER OF TECHNIQUES and pharmacologic agentshave been evaluated for their ability to trigger cardiac
preconditioning in the perioperative setting. The most promis-
ing to date have been ischemia1 and volatile anesthetic agents.2
Opioids have been demonstrated to provide cardiac protection
against ischemia reperfusion injury in a number of animal
models3 with the delta opioid receptor (OR) the predominate
subtype implicated in mediation.4 However, very few studies
have examined the clinical potential for opioid cardioprotec-
tion. Myocytes have been shown to be sites of endogenous
opioid synthesis, storage and release5 and opioid levels are
elevated during times of stress such as ischemia.6 Interestingly,
opioids also have an important role in mammalian hibernation.
This is a protective strategy to prolong survival of the brain and
peripheral organs since this energy-conserving state is associ-
ated with depletion of energy stores, intracellular acidosis and
hypoxia, similar to the conditions of ischemia. During hiber-
nation, circulating levels of opioid peptides are increased dra-
matically, and administration of opioid antagonists can effec-
tively reverse hibernation. Experimentally, opioids have been
shown to open the potassium ATP channels of mitochondria7
and reduce the opening of the mitochondrial permeability tran-
sition pore,8 a putative end effector of cardioprotection.9
At present, neither the plasma concentration of opioids nor
the duration of exposure required to induce clinical cardiac
protection have been defined. In addition, different opioid
receptor subtype activation may confer different degrees of
ischemic tolerance.10 Remifentanil, an ultra-short acting opioid,
has been shown to trigger both immediate and delayed cardiac
preconditioning in the rat heart.11,12 Although relatively selec-
tive for the  opioid receptor, its in vivo cardiac protection can
be blocked by antagonists of all three opioid receptor sub-
types.11 This study aimed to investigate whether the addition of
remifentanil to an otherwise standardized anesthetic technique
would reduce myocardial damage from cardiopulmonary by-
pass.
METHODS
Patient Selection
This study protocol was approved by the Institutional Ethical Com-
mittee at the Sun Yat-Sen Cardiovascular Hospital, Shenzhen, China,
and informed written consent was obtained from all study subjects.
Patients scheduled for first time elective, on pump coronary artery
bypass surgery for at least 3 diseased vessels were recruited. Exclusion
criteria included patients with a Tu score of 9, concomitant valve
surgery, an ejection fraction of less than 30%, recent myocardial
infarction (4 weeks), uncontrolled hypertension, congestive cardiac
failure, atrioventricular or left bundle branch block, any hepatic, renal,
or pulmonary disease, any allergy to trial medications, body weight
100 kg or chronic opioid consumption. The Tu score is a 6-variable
risk index that derives a score based on age, sex, left ventricular
function, type of surgery, urgency of surgery, and repeat operation.13 It
has been validated to predict mortality and length of ICU stay follow-
ing cardiac surgery.14,15 Patients’ medications were continued up to the
morning of surgery except for angiotensin converting enzyme inhibi-
tors. Antiplatelet therapy (including aspirin or nonsteroidal anti-inflam-
matory drugs) was stopped at least 1 week prior to surgery. Patients
were allocated to either the remifentanil (group R) or control group
(group C) by block randomization.
Anesthesia and Surgery
All operations on study subjects were performed by the same sur-
geon, anesthesiologist, and perfusionist. The drug infusion was pre-
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pared by another anesthesiologist not involved with the case. The
patients’ anesthesiologist and intensive care unit (ICU) physicians were
blinded to group allocation in this investigation. All clinical data were
recorded by a clinical research assistant not involved with the clinical
care of the patient.
Anesthesia
All patients received premedication with intramuscular morphine
(0.1 mg/kg) and scopolamine (5 g/kg) 30 minutes before the opera-
tion. After admission to the operation theatre, oxygen was administered
via a face mask at 5 L/min whilst intravenous and arterial line access
was established under local anesthesia. They were monitored with
5-lead ECG, pulse oximetry, capnography, invasive arterial pressure,
and pulmonary artery pressure during the operation. Anesthesia was
induced with a titrated dose of etomidate until loss of eyelash reflex,
followed by a bolus of fentanyl (5 g/kg). Pancuronium (0.15 mg/kg)
was used for muscle relaxation and tracheal intubation was performed
2 minutes later. Anesthesia was maintained in both groups with an
infusion of propofol (Diprivan; Astra Zeneca, Italy), which was com-
menced at a rate of 60 mcg/kg/min and titrated according to clinical
response. Patients in group R received a remifentanil bolus of 1 g/kg
followed by an infusion at a rate of 0.5 g/kg/min for 30 minutes. This
was predicted to produce a blood concentration of around 12 ng/mL.16
Five minutes before the end of the infusion, fentanyl was given in
increments to a total dose of 20 g/kg, prior to sternotomy. Patients in
the control group received 0.9% saline instead of remifentanil given at
the same infusion rate. The mean arterial pressure was maintained
within 20% of the pre operative value and above 60 mmHg. This was
achieved either with boluses of 0.5 g/kg phenylephrine to increase
arterial pressure or increasing the dose of propofol or the use of
glyceryl trinitrate to reduce arterial pressure. At the conclusion of the
operation, propofol sedation was continued in the intensive care unit.
Hemodynamic Monitoring
The right internal jugular vein and left radial artery were used for
hemodynamic monitoring. Heart rate (HR), mean arterial pressure
(MAP), pulmonary capillary wedge pressure (PCWP), central venous
pressure (CVP) , cardiac index (CI), systemic vascular resistance index
(SVRI), and left ventricular stroke work index (LVSWI) were moni-
tored using a radial arterial catheter and Swan-Ganz catheter (Space
Labs). Data were collected at baseline, preaortic cross clamp (ACC),
and 10 minutes, 2, 6, 12, and 24 hours postaortic cross clamp release
(ACCR), which was designated as T  0. In this study intraoperative
hypotension was defined as 30% less than that at baseline for a patient
with hypertension, or a MAP below 60 mmHg.
Cardiopulmonary Bypass
The Stockert-II heart-lung machine with roller pump and Affinity
membrane oxygenator (Medtronic) were used. The CPB circuit, the
oxygenator, and the arterial filter (Xi Jing, Xian, China) were primed
with 1500 mL of Ringer’s lactate containing 0.5 g/kg of mannitol and
5000 IU of heparin. In both groups heparin was administered at a dose
of 3 mg/kg to achieve an activated clotting time (ACT) of 480 seconds
or greater before commencement of CPB. The nonpulsatile pump flows
were adjusted to maintain a cardiac index between 2.4 L/min/m2 and
2.6 L/min/m2. Anterograde intermittent administration of a cold car-
dioplegic solution, histidine-triptophan-ketoglutal (HTK; Custodial Dr.
Koehler Chemie GMBH, Alsbach-Haenlein, Germany) was adminis-
tered both through the aortic root and through the graft after completion
of each distal anastomosis.
Laboratory Assay
Blood samples were collected from each patient after measuring
hemodynamic indices (see above). Samples were cooled to 4°C and
centrifuged at 3000 rpm for 10 minutes at 4°C. Serum was stored at
70°C until assay. Serum levels of heart-type fatty acid-binding pro-
tein (h-FABP) were measured by enzyme-linked immunosorbent assay
(IgCon Therapeutics Co. Ltd, Shanghai, China). Ischemia-modified
albumin (IMA) levels were measured by the albumin cobalt binding
test on a Cobas Mira Plus analyzer (Roche). The albumin cobalt
binding method has been validated in previous studies.13,17 Free cobalt
can be measured with spectrophotometric methods and this indicates
the IMA level. The cutoff point of IMA for myocardial ischemia was
accepted as 85 U/L according to the manufacturer’s recommenda-
tion.18,19 Levels of MB isoenzyme of creatine kinase (CK-MB) were
calculated using the photometric method (DiaSys Diagnostic System
GmbH, Holzheim, Germany). Cardiac troponin I (cTnI) levels were
measured using immunometric technology (Chuanzhi Biomedical
Products Corp., Taiyuan, China). The detection range for cTnI was
0.1-50 ng/mL, and a cTnI value above 0.5 ng/mL was considered as
abnormal.
ELECTROCARDIOGRAPHIC CHANGES
A 12-lead electrocardiogram was recorded preoperatively
and then daily postoperatively. The electrocardiographic diag-
nosis criteria for perioperative myocardial infarction (PMI) was
1 or more of more of the following: new Q waves of more than
0.04 seconds; a reduction in R waves of more than 25% in at
least 2 leads; significant ST segment deviation (elevation at the
J point in 2 or more contiguous leads with cut-off point  0.2
mV in leads V1, V2, or V3, and  0.1 mV in other leads) or T
wave abnormalities in 2 or more contiguous leads and new left
bundle branch block. Intra-operative arrhythmia was consid-
ered as 1 of the following: atrioventricular block, sustained
premature ventricular contractions, ventricular tachycardia, atrial
or ventricular fibrillation.
Criteria for Inotrope Administration
Inotrope support was considered in the post bypass period if
1 or more of the following occurred: (1) mean arterial pressure
was less than 60 mmHg or decreased more than 20% from the
baseline value; (2) cardiac output index (CI) was less than 2.2
L/min/m2 or (3) CVP or PCWP was more than 12 mmHg. For
the latter, nitroglycerin (1 to 10 g/kg/min) or sodium nitro-
prusside (0.5 to 10 g/kg/min) was administered in addition to
inotrope support. Dopamine was initially administered at a dose
of up to 5 g/kg/min. If there was no improvement, the dose of
dopamine would then either be increased or changed to a
combination of dobutamine (5 g/kg/min) plus epinephrine
starting at 0.03 g/kg/min. An intra-aortic balloon pump was
considered if the epinephrine dose reached 0.1 g/kg/min. The
patient’s inotrope requirement was classified as none, mild
(dopamine  5  g/kg/min) or moderate (dopamine  5
g/kg/min or dobutamine 5 g/kg/min or epinephrine  0.1
g/kg/min).
Statistical Analysis
Sample size was calculated using cardiac troponin levels as
the primary outcome. A minimum detected difference of 0.5
ng/mL at T  6 between groups was considered significant. A
sample size of at least 14 was required to achieve a power of
0.9 and a 2-sided  error of 0.05. Categorical variables are
presented by their number, summarized as a percentage and
compared using 2 or Fisher’s exact test where appropriate.
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Comparisons of continuous variables between groups were
analyzed by unpaired t test. The time course of hemodynamic
data was analyzed between groups by 2-way ANOVA for
repeated measurements. When a significant overall effect was
detected, Tukey’s honest significance difference test was per-
formed to compare single mean values. Data for the biochem-
ical markers (CK-MB, cTnI, IMA, and h-FABP) were analyzed
for normality with the Kolmogorov-Smirnov test. Nonparamet-
ric data were compared at each time point using the Mann
Whitney U test. Comparison of the areas under the curve for all
the markers was also made using unpaired t test. Differences
were considered significant at a value of p  0.05. Statistical
analyses were performed using the SPSS statistical software
package, version 13.0 (SPSS Inc., Chicago, IL).
RESULTS
Forty patients were recruited and randomized into either the
control (n 20), or remifentanil group (n 20). There were no
significant differences in patient characteristics in terms of
demographics, medications, preexisting medical conditions,
laboratory results and cardiac function (Table 1). Surgical
revascularization was successfully achieved in all patients and
there were no differences in surgical and perfusion parameters
between groups.
The results of the primary outcome of biochemical marker
release are shown in Figure 1A to 1D. As the values for the
biochemical markers of myocardial ischemia and cellular dam-
age did not have a Gaussian distribution, they were processed
in a nonparametric fashion. There were elevations in all tested
markers after CPB when compared with baseline. They re-
turned to baseline values at T  6 for IMA and T  24 for
h-FABP. The remifentanil group had lower levels of CK-MB at
T  2, 6, 12, and 24 hours and lower cTnI at T  10 minutes,
2, 6, and 12 hours. IMA levels were lower at T  10 minutes
and 2 hours as were the h-FABP levels at these times as well as
at T  12 hours.
Although not powered for clinical outcome parameters, there
were some trends noted between the 2 groups. These included
significantly more patients with episodes of arrhythmia in the
control group. In addition there were more patients in the
control group that required defibrillation to restore sinus
rhythm after reperfusion (Table 2).
In the pre bypass period, patients in the remifentanil group
had lower MAP as well as systemic vascular resistance index.
In the first 2 hours (T  2) following the release of the aortic
cross clamp (T  0) the remifentanil group had significantly
greater left ventricular stroke work index and cardiac index
(Table 3). Post operatively there were fewer patients requiring
inotrope support in the remifentanil group and, for those that
did, infusion rates were lower. One patient in the control group
developed a postoperative myocardial infarction that later re-
quired IABP support. More patients had ECG changes postop-
eratively in the control group. The time to tracheal extubation
was shorter in patients in the remifentanil group. However, the
overall length of ICU and hospital stays was not different
between the 2 groups and there were no deaths in any of the
patients in the study (Table 4).
DISCUSSION
Results from this study suggest that a short period of high
dose remifentanil before cardiopulmonary bypass confers a
preconditioning effect over and above that provided by fenta-
nyl. From laboratory data, there was an increase in infarct
sparing effect with increasing dose of remifentanil.11 Clinically,
blood concentrations of 4-8 ng/mL produce little further reduc-
tion in the minimal alveolar concentration of isoflurane (a
measure of opioid potency)20 and a blood concentration of 7.5
ng/mL depresses the epinephrine response to pneumoperito-
neum and surgery.21 An infusion regime was, therefore, chosen
that would produce blood concentrations of around 12 ng/mL
which is a dose sufficiently high to reduce the stress response
of surgery. The 30-minute infusion period was chosen as lab-
oratory data showed that three 5 minute infusions of remifen-
tanil interspersed with 5-minute infusion free periods (a total of
30 minutes) was sufficient to demonstrate a preconditioning
response in our animal studies. A decision was made not to
Table 1. Preoperative Patient Data
Variables Group C (n  20) Group R (n  20)
Demographics
Age (y) 65.6  3 64.50  2
Sex (M/F) 15/5 14/6
Weight (kg) 69.50  10.2 68.10  7.6
BSA (m2) 1.69  0.41 1.72  0.34
Preoperative medications
 blockers 14 13
Calcium blockers 7 8
ACE inhibitors 8 9
Nitrates 16 17
Diuretics 5 5
Sulfonylurea 4 3
Insulin 6 5
Aspirin 14 15
Other diseases
Diabetes 7 6
Hypertension 7 8
COPD 3 2
Peripheral Vascular Disease 2 1
Tu Score 3.14  0.4 3.05  0.3
Laboratory test
Hemoglobin (g/L) 125.5  23.2 123.7  11.6
Platelet count (109/L) 215.5  36.7 224.2  48.5
ALT 20.1  7.5 18.7  3.1
AST 31.2  10.3 30.6  12.3
Albumin (g/L) 42.2  7.5 41.1  3.1
Urea (mol/L) 233.2  57.3 219.6  48.2
Creatinine (mol/L) 120.3  36.5 104.3  20.1
Cardiac status
Previous MI (4 weeks) 8 9
LVEF 30%-49%, 4 5
LVEF  49%, 16 15
LMCA stenosis  50% 14 15
NOTE. Data are presented as mean  SD or number (n).
Abbreviations: BSA, body surface area; ACE, angiotensin-convert-
ing enzyme; COPD, chronic obstructive pulmonary disease; ALT, ala-
nine aminotransferase; AST, aspartate aminotransferase; MI, myocar-
dial infarction; LVEF, left ventricular ejection fraction; LMCA, left main
coronary artery; NS, not significant.
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pulse the delivery of remifentanil to avoid hemodynamic insta-
bility that such a regime may introduce. Once triggered, a
preconditioning response should have a protective window of
several hours and the concentrations of remifentanil should
have dissipated by the time of cross clamping.
A number of agents including those used in the perioperative
period have been demonstrated to protect the myocardium. This
study attempted to minimize the use of such agents as they
could have acted as confounders, and other drug use was the
same in both groups. Propofol was used rather than a volatile
anesthetic as certain volatile agents have been shown to confer
acute preconditioning.22,23 Propofol too has been shown in 1
study to protect the heart during bypass surgery, probably via
its antioxidant properties.24 During the remifentanil infusion
period, the control group may have temporarily received a
higher dose of propofol than the remifentanil group, which may
potentially reduce the differences between groups. However,
the dose used in the control would have been less than that
shown to be cardioprotective. As it would be unethical to
exclude the use of opioids in cardiac surgical patients, the same
dose of fentanyl was used in both groups to equalize the effect
this opioid may have had on outcome. Any difference in
potency between fentanyl and remifentanil should, therefore,
not affect the outcome. In addition to the conventional markers
of cardiac damage after cardiopulmonary bypass (CKMB and
cardiac troponin I)25, we also employed 2 innovative markers
that are not routinely used. Ischemia modified albumin (IMA)
is a metabolic variant of albumin that may represent an innate,
endogenous response to ischemia.26 In addition to myocardial
ischemia,18,27 its level is increased in acute stroke28, skeletal
muscle ischemia29 and pulmonary embolism.30 It has reduced
binding capacity to transition metals such as cobalt, copper or
nickel and this property is exploited during laboratory measure-
ments. It has rapid kinetics, rising within 30 minutes and
Fig 1. Blood levels of biochemical markers over time. Values are plotted as median (error bars interquartile range). Pre-ACC, period before
aortic cross clamp was applied; ACCR, aortic cross clamp release. p < 0.05.
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returning to baseline within 12 hours after percutaneous angio-
plasty procedures.18 Heart type fatty acid binding protein
(hFABP) is a small water soluble intracellular protein that
resides in the cytoplasm.31 Due to its small size, it is rapidly
released into the bloodstream following sarcolemmal damage.32
It has been shown to peak as early as 60 minutes after reper-
fusion following cardiopulmonary bypass, much earlier than
CKMB and troponin.33,34
As opioids were used in both groups, interpretation of these
results must be tempered with caution as it may be accounted
for by a number of possible explanations. First, there could be
a difference in cardioprotective properties between remifentanil
and fentanyl due to a different affinity for opioid receptor
subtypes, as all other anesthetic and surgical factors were
similar in both groups except for the use of remifentanil. We
feel that this is an unlikely explanation. Remifentanil is chem-
ically related to fentanyl and both are predominantly  opioid
receptor agonists.35 Remifentanil also has some action on delta
and, to a lesser extent, kappa opioid receptors.36 The cardiac
preconditioning effect of remifentanil in vivo can be blocked
Table 2. Intraoperative Data
Variable Group C (n  20) Group R (n  20) p Value
Pre bypass fluids (mL) 854  138 869  142 0.73
Patients requiring phenylephrine pre bypass (n) 10 17 0.02
Post bypass fluids (mL) 1327  372 1294  331 0.75
HTK (mL) 1841  248 1715  269 0.14
Aortic cross-clamping time (min) 78  12 75  8 0.38
Aortic side-clamping (min) 41  13 39  5 0.59
CPB time (min) 152  28 147  34 0.59
Operation time (min) 248  35 236  33 0.27
Number of grafts 3.2  0.7 3.1  0.5 0.61
Number of patients requiring cardioversion to
restore rhythm after CPB (n) 8 2 0.03
Dopamine time (min) 56  20 48  17 0.17
Dopamine average dose (g/kg/min) 3.51  0.57 2.78  1.61 0.06
Phenylephrine (mg) 0.21  0.06 0.23  0.09 0.41
Propofol (mg) 1120  203 1204  251 0.25
Fentanyl (g) 1.75  0.2 1.7  0.2 0.43
Post bypass adverse events
Bradycardia (n) 4 5 1.0
Hypotension (n) 5 6 1.0
Arrhythmias (n) 8 2 0.03
NOTE. Data are presented as mean  SD or number (n).
Abbreviations: Arrhythmia, atrioventricular block, sustained premature ventricular contractions, ventricular tachycardia, atrial or ventricular
fibrillation occurring after separation from cardiopulmonary bypass but before arrival in ICU. HTK, histidine-triptophan-ketoglutala, a type of
cardioplegia solution; CPB, cardiopulmonary bypass.
Table 3. Patients’ Perioperative Hemodynamic Data
Variable Group Baseline Pre-ACC
Post-ACCR
10 min 2 hours 6 hours 12 hours 24 hours
HR (beats/min) C 72  14 75  14 68.2  11 82  14 85  20 79  10 83  8
R 74  20 76  18 70.6  20 88  25 83  23 80  16 88.  11
MAP (mmHg) C 94  14 88  20 64  15 83  13 88  10 85  20.3 88  17
R 90  18 70  13# 71  22 86  17 88  12 83  18 90  18
CVP (mmHg) C 8  1 8  2 9  2 9  2 9  1 10  1 11  3
R 8  2 8  2 9  2 9  2 9.  1 10  1 11  4
PCWP (mmHg) C 8  1 8  1 7  1 8  1 9  1 10  1 12  4
R 8  1 7  1 7  1 8  1 9  1 10  1 12  3
CI (L/min/m2) C 1.9  0.1 1.9  0.2 2.0  0.3 2.2  0.3 2.5  0.6 2.6  0.3 2.4  0.3
R 1.8  0.2 2.7  0.2# 2.3  0.3 2.5  0.13# 2.5  0.3 2.5  0.4 2.5  0.2
SVRI (dynes  s  cm5/m2) C 2984  526 2606  437# 2448  371 2506  417 2671  315 2318  329 2571  344
R 2738  369 1872  238 2287  318 2482  339 2581  403 2481  278 2392  276
LVSWI (g  m/m2) C 25.5  9 30.5  8.4 34.1  12.3 37.6  9.1 38.5  7.4 37.3  9.3 38.5  12.7
R 28.3  22 31.3  9.2 43.3  8.# 48.2  10.2# 43.3  11.5 41.4  8.5 40.3  10.4
NOTE. Data are presented as mean  SD.
Abbreviations: #, difference between control and remifentanil groups (p  0.05); C, control group; R, remifentanil group; ACC, aortic
cross-clamping; ACCR, aortic cross clamp release; HR, heart rate; MAP, mean arterial pressure; CVP, central venous pressure; PCWP, pulmonary
capillary wedge pressure; CI, cardiac index; SVRI, systemic vascular resistance index; LVSWI, left ventricle stroke work index.
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by  and  as well as mu receptor antagonists.11,37 However,
this observation may also be a result of functional interaction or
“cross talk” between different opioid receptor subtypes,38,39
whereby activation or blockade of 1 subtype could possibly
influence other subtypes. Fentanyl can also protect the heart in
vitro via the delta receptor.40 However, there is little data
directly comparing the opioid receptor subtype affinity in car-
diac tissue between fentanyl and remifentanil.
It is more likely that the results are simply a function of the
difference in the total dose of opioid given. The potency of
remifentanil is similar to fentanyl.41 A higher plasma concen-
tration of total opioid in the remifentanil group may have had
a more powerful agonist effect on the appropriate receptors on
a greater number of cells in a heart with diseased vessels. This
could have clinical implications for patients undergoing on
pump cardiac surgery. High doses of opioids were commonly
used for cardiac anesthesia in the past42 but have now been
substantially reduced, commensurate with the trend towards
fast track surgery. Remifentanil, however, has unique pharma-
cokinetic properties that allow rapid onset of high target opioid
concentrations intraoperatively with very rapid recovery on
cessation of infusion avoiding the usual consequence of pro-
longed respiratory depression.41,43 Studies comparing the use of
remifentanil versus fentanyl in this setting have concluded that
remifentanil is safe and suitable for fast track surgery.44,45
Furthermore in these studies, there were indications that higher
opioid doses may be beneficial. There were fewer patients
suffering myocardial infarction in the remifentanil and high
dose fentanyl group compared with a low dose fentanyl group
in the study by Myles and colleagues.45 In 2 other studies there
was also a trend towards lower CKMB levels in the remifen-
tanil group in 144 and statistically lower CKMB and a trend
towards lower troponin T levels in the other.46 However, in the
latter 2 studies volatile anesthetic agents were also used and
that may have influenced the results.
There are several limitations to this study. This was a small
study that was not statistically powered to judge certain clinical
outcomes such as the incidence of death or myocardial infarc-
tion. As mentioned, it was not possible to avoid the use of
opioids in the control group as this is standard practice in
cardiac anesthesia and, therefore, fentanyl was used. It follows
that any anticipated difference between the 2 groups would be
small and hence our choice of 0.5 ng/mL as a significant
difference when calculating the study power. Plasma drug
concentrations were not measured and, since only a single dose
was used, there is no dose response data. The results do suggest
that either remifentanil or an increased overall opioid dose is
beneficial but the question of whether 1 opioid is superior to
another remains unanswered.
Oxidative stress as a result of reperfusion injury is a known
causative factor of cardiac muscle injury and may occur after
cardiac bypass.47 Myocardial reperfusion injury is also seen
after the use of primary percutaneous coronary intervention
following myocardial infarction where it has been suggested
that this may account for significant morbidity and up to 50%
of the final size of the infarct.48,49 Pharmacologic attempts to
target known mediators of this process have generally been
ineffective, although, recently, cyclosporine administered im-
mediately before primary PCI significantly reduced the release
of CK, cTnI and infarct size.50 Perhaps remifentanil may be
worthy of further study in this setting.
In conclusion, the results from this study demonstrate that
the addition of high doses of remifentanil prior to sternotomy,
reduced cardiac injury during on pump coronary artery bypass
surgery as manifest by a reduction in the release of a range of
biochemical markers. High dose opioids, particularly in con-
junction with the pharmacokinetics of remifentanil, may rep-
resent a clinically simple and safe technique for cardiac pre-
conditioning.
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